AU757803B2 - Gene therapy for regulating smooth muscle cell tone - Google Patents

Gene therapy for regulating smooth muscle cell tone Download PDF

Info

Publication number
AU757803B2
AU757803B2 AU55728/99A AU5572899A AU757803B2 AU 757803 B2 AU757803 B2 AU 757803B2 AU 55728/99 A AU55728/99 A AU 55728/99A AU 5572899 A AU5572899 A AU 5572899A AU 757803 B2 AU757803 B2 AU 757803B2
Authority
AU
Australia
Prior art keywords
smooth muscle
protein
bladder
dna
maxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU55728/99A
Other languages
English (en)
Other versions
AU5572899A (en
Inventor
George J. Christ
Arnold Melman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of AU5572899A publication Critical patent/AU5572899A/en
Application granted granted Critical
Publication of AU757803B2 publication Critical patent/AU757803B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU55728/99A 1998-08-18 1999-08-18 Gene therapy for regulating smooth muscle cell tone Ceased AU757803B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13584998A 1998-08-18 1998-08-18
US09/135849 1998-08-18
PCT/US1999/018912 WO2000010604A1 (en) 1998-08-18 1999-08-18 Gene therapy for regulating smooth muscle cell tone

Publications (2)

Publication Number Publication Date
AU5572899A AU5572899A (en) 2000-03-14
AU757803B2 true AU757803B2 (en) 2003-03-06

Family

ID=22469993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55728/99A Ceased AU757803B2 (en) 1998-08-18 1999-08-18 Gene therapy for regulating smooth muscle cell tone

Country Status (6)

Country Link
EP (1) EP1126879A4 (de)
JP (1) JP2002523380A (de)
KR (1) KR100596884B1 (de)
AU (1) AU757803B2 (de)
CA (1) CA2339800A1 (de)
WO (1) WO2000010604A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271211B1 (en) 1997-02-13 2001-08-07 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for regulating penile smooth muscle tone
US7030096B1 (en) 1997-02-13 2006-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of enhancing relaxation of penile smooth muscle by introduction of DNA encoding maxi-K potassium channel protein
CN1252261C (zh) * 2000-08-30 2006-04-19 株式会社无细胞科学 无细胞蛋白质合成用转录模板的设计、构建及使用其的稀释分批式麦胚芽无细胞蛋白质的合成法
US7491385B2 (en) 2001-09-05 2009-02-17 Genegrafts Ltd. Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2006084322A1 (en) * 2005-02-09 2006-08-17 Craig Steven Mclachlan Treatment method for modifying tissue passive electrical conductance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014748A1 (en) * 1994-11-10 1996-05-23 Nirec, Inc. AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH iNOS, AND RELATED NOS AGENTS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523497D0 (en) * 1995-11-16 1996-01-17 Ashcroft Frances Cell membrane protein and application thereof
GB9701867D0 (en) * 1997-01-30 1997-03-19 Isis Innovation Materials and methods relating to cell membrane proteins
CA2279577A1 (en) * 1997-02-04 1998-08-06 Valentis, Inc. Treatment for urinary incontinence using gene therapy techniques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014748A1 (en) * 1994-11-10 1996-05-23 Nirec, Inc. AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH iNOS, AND RELATED NOS AGENTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRIST ET AL(1997) MOLECULAR UROLOGY 1(1) 45-54 *

Also Published As

Publication number Publication date
EP1126879A4 (de) 2004-08-04
KR100596884B1 (ko) 2006-07-04
JP2002523380A (ja) 2002-07-30
KR20010085416A (ko) 2001-09-07
AU5572899A (en) 2000-03-14
CA2339800A1 (en) 2000-03-02
EP1126879A1 (de) 2001-08-29
WO2000010604A1 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
Zhang et al. Ghrelin stimulates neurogenesis in the dorsal motor nucleus of the vagus
Christ et al. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function
Krewson et al. Transport and elimination of recombinant human NGF during long-term delivery to the brain
US6780836B2 (en) Method of promoting angiogenesis using relaxin
KR100535782B1 (ko) 발기 부전을 완화시키기 위한 유전자 치료제
US6271211B1 (en) Gene therapy for regulating penile smooth muscle tone
KR101397912B1 (ko) 여드름 및 기타 질환 치료용 비스파틴 치료제
KR20090063209A (ko) 신경병증성 통증에서 진통의 유도
US20070086982A1 (en) Gene therapy for regulating smooth muscle tone
US6239117B1 (en) Gene therapy for regulating bladder smooth muscle tone
JP2009138004A (ja) 血管新生因子の皮膚疾患への遺伝子導入
US20140088176A1 (en) Gene transfer for regulating smooth muscle tone
AU757803B2 (en) Gene therapy for regulating smooth muscle cell tone
Bereiter et al. Selective blockade of substance P or neurokinin A receptors reduces the expression of c-fos in trigeminal subnucleus caudalis after corneal stimulation in the rat
Chien et al. Renal afferent signaling diuretic response is impaired in streptozotocin-induced diabetic rats
Leiguarda et al. Intrathecal administration of an anti‐nociceptive non-CpG oligodeoxynucleotide reduces glial activation and central sensitization
US20220133849A1 (en) Compositions and methods for the treatment of smooth muscle dysfunction
EP1827602B1 (de) Modulierung der retinalen pigmentierten epithel-permeation durch hemmung von vegfr-1
AU2002317634B2 (en) Modulation of insulin-regulated aminopeptidase (IRAP)/Angiotensin IV (AT4) receptor activity
Angeloni Development of Sonic hedgehog as an erectile dysfunction treatment
Thakor Development of a novel sensory neuron gene delivery platform with concomitant investigation of messenger ribonucleic acid translocation for the NaV1. 8 sodium channel during neuropathic pain

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)